CLINICAL_TRIALS
trial_result
· 2012-04-27
Clinical Trial Update: Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC) [Phase 2]
Summary
A Phase 2 study of M200 (volociximab) in metastatic renal cell carcinoma was terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Abbott | Conditions: Renal Cell Carcinoma, Metastases | Phase 2 | Status: TERMINATED